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Abstract
Background: Chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-
seq) is increasingly being applied to study transcriptional regulation on a genome-wide scale. While
numerous algorithms have recently been proposed for analysing the large ChIP-seq datasets, their
relative merits and potential limitations remain unclear in practical applications.
Results: The present study compares the state-of-the-art algorithms for detecting transcription
factor binding sites in four diverse ChIP-seq datasets under a variety of practical research settings.
First, we demonstrate how the biological conclusions may change dramatically when the different
algorithms are applied. The reproducibility across biological replicates is then investigated as an
internal validation of the detections. Finally, the predicted binding sites with each method are
compared to high-scoring binding motifs as well as binding regions confirmed in independent qPCR
experiments.
Conclusions:  In general, our results indicate that the optimal choice of the computational
approach depends heavily on the dataset under analysis. In addition to revealing valuable
information to the users of this technology about the characteristics of the binding site detection
approaches, the systematic evaluation framework provides also a useful reference to the
developers of improved algorithms for ChIP-seq data.
Background
Chromatin immunoprecipitation (ChIP) enables the
identification of in vivo protein-DNA interactions under a
given condition or in a particular cell type. An important
application is the detection of transcription factor binding
sites to characterize the regulatory networks controlling,
for instance, various cellular processes or physiological
states. The high-throughput ChIP techniques are based on
identifying on a global scale the sequences and genomic
locations of the immunoprecipitated DNA fragments that
are bound by the transcription factor of interest. The most
common approach until now has been to hybridize the
DNA fragments to a tiling microarray (ChIP-chip) [1].
However, the fast development of the next-generation
massively parallel sequencing technologies, which enable
the direct sequencing of the DNA (ChIP-seq), has recently
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challenged the microarray-based experiments, providing
an alternative particularly useful to study organisms with
less well characterized genomes [2,3].
ChIP-seq involves the sequencing of the ChIP-enriched
DNA fragments for ~30 bp from their ends. These short
sequence reads (tags) are then aligned to a reference
genome and binding sites are identified on the basis of
their significant accumulation at particular genomic loci
using various peak detection algorithms [4]. In addition
to a list of genomic regions predicted to be bound by the
transcription factor, each potential binding site is typically
characterized by the number of reads it contains or the
height of the peak determined by the number of overlap-
ping reads. The predicted binding regions can then be
used for downstream analyses, such as motif discovery
and annotation, to provide further functional context for
the biological interpretation.
Together with the development of the ChIP-seq technol-
ogy, a burst of methods has been introduced for analysing
the resulting datasets. In general, these binding site detec-
tion algorithms can be divided into window-based
approaches, which first define the start and end of a can-
didate region and then count the number of reads within
it (e.g. CisGenome [5]), or overlap-based approaches,
which first identify the peaks on the basis of local maxima
over read overlaps and then set the start and end of the
corresponding candidate region (e.g. FindPeaks [6]). In
addition, a method based on hidden Markov models
(HMM) is available, which describes the read accumula-
tion along the genome as a sequence of two different
states: binding sites and background [7].
The ChIP-seq experiments, in turn, can be divided into
those involving negative control samples and those that
contain only ChIP samples. The main difference in analys-
ing these datasets is that the former allow the statistical
significance of the peaks to be estimated on the basis of an
empirical background. Accordingly, some of the current
algorithms are applicable only when a control sample is
available (e.g. QuEST [8]), while some are not designed to
incorporate control data (e.g. GeneTrack [9]); however,
most of the algorithms provide different variants depend-
ing on the type of the data (e.g. MACS [10]).
While several recent publications have introduced new
algorithms for ChIP-seq data analysis and the authors
have shown improved performance over the previous
approaches in selected datasets, an independent compari-
son of their relative performance using common datasets
is still lacking. At the moment, there is only limited infor-
mation on the use of the different approaches in practical
applications; what are their relative merits and limita-
tions; or are there actually large differences between the
methods.
The present study compares systematically the perform-
ance of the different peak detection algorithms in predict-
ing transcription factor binding sites in ChIP-seq data. In
particular, we compare nine publicly available algorithms
that represent the current state-of-the-art of the field:
PeakFinder [2], GeneTrack [9], FindPeaks [6], SISSRs [11],
QuEST [8], MACS [10], CisGenome [5], PeakSeq [12], and
Hpeak [7] (Table 1). The focus here is on evaluation meas-
ures that are of practical interest to researchers when ana-
lysing their datasets. First, we point out potential
differences in the biological conclusions made when dif-
ferent methods are applied. Then, we evaluate the detec-
tions in terms of their reproducibility across biological
replicates. Finally, we investigate the overlap of the pre-
dicted binding sites with the corresponding sequence
motifs or binding regions confirmed in independent
qPCR experiments. Since our aim is to give an objective
and practical assessment of the algorithms, we apply each
method using their default parameters and following the
instructions provided in the software manuals. Systematic
comparisons are shown in four diverse datasets (Table 2).
In addition to three publicly available datasets, against
which any future algorithm can be easily compared, we
also include into the evaluations our in-house ChIP-seq
data on the binding of the STAT6 transcription factor to
account for the fact that some of the datasets have been
used to train particular algorithms and their default
parameters may therefore be ideal for these data.
Methods
Peak detection algorithms
A short summary of the algorithms being compared in the
present study is given below. For more details, the reader
is referred to the original publications or the software
websites (Table 1). When applying the algorithms, we fol-
lowed the instructions and recommendations given in the
software manuals as closely as possible to provide a fair
evaluation. In particular, the default values for the param-
eters were used, which is likely to be the choice of most
average users.
PeakFinder identifies candidate binding sites as aggrega-
tions of k or more ChIP reads not separated by more than
n bp (default 75) and with an additional requirement that
at least 5 of the reads are overlapping. If a control sample
is available, then it is further required that there is at least
an m-fold enrichment (default 5-fold) of reads in the ChIP
sample over the control within the same boundaries, and
the data are recommended to be normalized into num-
bers on a per-million reads basis. Following the default
settings, we used k = 20 when a ChIP sample was analysed
without a control, and k = 8 when a control sample wasBMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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Table 1: Peak detection algorithms investigated in the present study
Algorithm Availability Reference Type Background
model
PeakFinder 2.0.1 http://woldlab.caltech.edu/html/chipseq_peak_finder [2] S, C none
GeneTrack 1.0.1 http://code.google.com/p/genetrack/ [9] S none
FindPeaks 3.1.9.2 http://www.bcgsc.ca/platform/bioinfo/software/findpeaks/ [6] S uniform
SISSRs
v1.4
http://sissrs.rajajothi.com/ [11] S, C Poisson/
control sample
QuEST
1.0
http://mendel.stanford.edu/sidowlab/downloads/quest/ [8] C control sample
MACS
1.3
http://liulab.dfci.harvard.edu/MACS/ [10] S, C local Poisson/
control sample
CisGenome
v1
http://www.biostat.jhsph.edu/~hji/cisgenome/ [5] S, C negative binomial/
control sample (binomial)
PeakSeq v1.01 http://www.gersteinlab.org/proj/PeakSeq/ [12] C local Poisson and
control sample (binomial)
Hpeak
1.1
http://www.sph.umich.edu/csg/qin/HPeak/ - S, C hidden Markov model
The column Type indicates whether the method is applicable to a single sample analysis (S) or a two-sample analysis involving a control sample (C).
Table 2: ChIP-seq samples analysed in the present study
Sample Cell type Binding motif
(Genomatix)
Reads (million) Reference
NRSF Jurkat V$NRSF.01 2.3 [2]
Control Jurkat - 1.7 [2]
NRSF mono Jurkat V$NRSF.01 5.4 [8]
NRSF poly Jurkat V$NRSF.01 8.8 [8]
Control Jurkat - 17.4 [8]
FoxA1 MCF7 V$HNF3.01 3.9 [10]
Control MCF7 - 5.9 [10]
STAT6 Th2 1 h V$STAT6.01 3.0 Elo et al. (unpublished)
STAT6 Th2 4 h V$STAT6.01 2.7 Elo et al. (unpublished)
STAT6 Thp V$STAT6.01 3.2 Elo et al. (unpublished)BMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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utilized. PeakFinder does not provide any estimates for
false discovery rate (FDR).
GeneTrack  applies a Gaussian smoothing procedure to
represent the read densities along the chromosomes.
More specifically, a normal distribution with a specified
standard deviation (default 20) is utilized. Peaks are iden-
tified by finding the local maxima in the smoothed data.
The results are reported for both strands separately as well
as for their composition (sum of the individual strands).
An optional exclusion zone parameter allows to deter-
mine a distance, within which only a single peak is iden-
tified. Since no guidance is provided on how to optimally
utilize the strand information nor how to define the exclu-
sion zone parameter in the context of transcription factor
binding, we focused here on the composite-strand detec-
tions with the exclusion zone set to 0. To reduce the large
number of identifications made due to these choices
(even millions of small peaks), we only considered peaks
having a score over 7, which is a compromise between the
default overlap and count requirements of PeakFinder.
GeneTrack does not provide any options to estimate the
FDR levels of the detections.
FindPeaks extends each aligned read directionally to an
estimated length of the DNA fragment. The candidate
binding sites are then identified on the basis of overlap-
ping fragments (peak height) along the genome. The FDR
is estimated using a Monte Carlo simulation, in which
random locations are repeatedly generated for the reads
and the number of peaks at a given height threshold in the
randomized data is divided by the number of peaks
observed at the same threshold in the real experimental
data. As suggested in the FindPeaks manual, the reads
were filtered to remove duplicate hits, the fragment length
distributions were estimated by assuming a triangle-based
distribution with a median value of 200, while enabling
directional peak detection, peak trimming and subpeak
detection modules. Peaks at FDR < 0.05 were identified.
SISSRs (Site Identification from Short Sequence Reads)
also starts by extending the reads to the estimated length
of the DNA fragment, similarly as FindPeaks. It then scans
the genome using a window of width w (default 20) and,
for each window, it subtracts the number of antisense
reads from the number of sense reads (called net tag
count). Binding sites are identified as transition points of
this count from positive to negative, provided that the
number of directional reads on each side of the inferred
binding site is at least n (default 2). A Poisson background
or a negative control sample, if available, is used to esti-
mate the FDR, which is determined as the ratio of the
number of peaks indicated by the background model to
the number of peaks observed in the real data. The default
FDR threshold of 0.001 was applied.
QuEST  (Quantitative Enrichment of Sequence Tags)
shares with GeneTrack the idea of applying a Gaussian
kernel separately to both strands (default bandwidth 30).
The major difference is that QuEST estimates a peak shift
between the strands before aggregating the results. More-
over, while GeneTrack does not provide any practical
guidance on how to choose a suitable threshold for a
peak, QuEST determines peak calls based on the proper-
ties of separate control data. In particular, the ratio of the
detected peak to the background is required to exceed a
specified threshold value, called the rescue ratio (default
10). If the negative control has enough reads (at least
approximately twice as many as the ChIP sample), then
also FDR estimation is provided, in which the control
sample is divided into two parts to mimic a random two-
sample comparison and FDR is estimated as the ratio
between the number of peaks detected in this random
comparison and the number of peaks detected in the
actual comparison in the real data with the same parame-
ters. QuEST does not support analyses without controls.
MACS  (Model-based Analysis of ChIP-Seq) is another
algorithm besides QuEST that takes advantage of the
observed bimodal enrichment patterns of binding sites by
empirically modelling the shift size. Unlike QuEST, how-
ever, it is applicable also without negative controls. To
capture local biases in the genome, a dynamic Poisson
distribution is used to model a local background. Candi-
date peaks with p-values below a user-defined threshold
(default p < 10-5) are identified. If negative control data
are available, then also FDR is estimated. More specifi-
cally, the same parameters are used to determine the
number of ChIP peaks over the control sample and the
number of control peaks over the ChIP sample, and the
FDR is defined by dividing the latter by the former. In the
present study, the default p-value threshold was applied.
CisGenome  scans the genome with a sliding window
(default width 100) and identifies regions with enriched
read counts. The FDRs are estimated assuming that the
background read occurrence follows a negative binomial
distribution, which was suggested to provide a better fit to
the real data than the (global) Poisson distribution [5].
The FDR is determined by calculating the ratio between
the number of peaks expected by the null model at a par-
ticular cutoff level and the observed number of peaks
detected at the same level. In the present study, we identi-
fied regions at FDR < 0.05, similarly as with FindPeaks. In
the presence of negative control data, a binomial model is
used to determine whether the read enrichment relative to
the control is significant. The distribution of the window-
based read counts in the ChIP sample is compared with
what is expected by a binomial distribution given the total
count in the ChIP and control samples. The default FDRBMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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threshold of 0.1 was considered. The directionality of the
reads was utilized to refine the peak boundaries.
PeakSeq first constructs a similar read density map as Find-
Peaks by extending the reads directionally to the average
length of the DNA fragments and determining their over-
lap along the genome. Similarly as in MACS, a candidate
set of peak regions is then identified in a ChIP-sample
assuming a local Poisson background, taking into account
also the variability in genomic mappability. Finally, the
significance of enrichment of these candidates is deter-
mined relative to a negative control sample using a bino-
mial distribution, similarly as in CisGenome, assuming
that under the null hypothesis the reads should occur with
equal likelihood from the ChIP and control sample. To
control FDR, the obtained p-values are adjusted using the
procedure of Benjamini and Hochberg [13]. The default
FDR threshold of 0.05 was used.
Hpeak identifies peaks using a two-state hidden Markov
model (HMM), whose states correspond to the binding
sites and the background. The emission probabilities are
described by two different Poisson distributions. The sig-
nificance of enrichment of the peaks is adjusted using the
Bonferroni correction for multiple testing. The default sig-
nificance threshold of 0.001 was applied.
Datasets
To compare the peak detection methods across diverse
studies, four different datasets were considered, which
measure the binding of three human transcription factors,
STAT6, NRSF (two datasets) and FoxA1 (Table 2). The
STAT6 data are from our unpublished study, whereas the
three other datasets are from publicly available sources.
All the datasets were sequenced using the Illumina's Sol-
exa sequencing technology [14].
Our in-house data measures the binding of STAT6 (signal
transducer and activator of transcription 6) transcription
factor in human T helper (Th) cells. One of the samples is
from naïve Th precursor (Thp) cells, whereas the other
two samples are activated and induced by IL4 to polarize
towards the Th2 subtype (measurements at 1 h and 4 h
after polarization). Further details about the data and the
biological conclusions will be presented elsewhere (Elo et
al., unpublished).
Two of the public datasets measure the binding of the
transcription factor NRSF (neuron-restrictive silencer fac-
tor) in Jurkat T cells. The first NRSF dataset is from the
study of [2] and was downloaded from the Illumina web-
site [15]. It contains one NRSF ChIP sample and a corre-
sponding negative control. The other NRSF dataset is from
the study of [8] and was downloaded from the QuEST
website. It contains a monoclonal and a polyclonal NRSF
ChIP sample as well as a control input sample. The FoxA1
data measures the binding of FoxA1 (hepatocyte nuclear
factor 3α) transcription factor in MCF7 cells. It contains
one FoxA1 ChIP sample and one input control sample.
The data were downloaded from the MACS website [10].
The STAT6 read data were aligned to the human reference
genome (NCBI v36) using the short oligonucleotide
alignment program SOAP [16]. The publicly available
datasets were already aligned in the original studies and
these preprocessed data were used. Only uniquely
mapped coordinates were considered for further analysis.
The number of aligned reads for the different samples var-
ied from 1.7 to 17.4 million (Table 2).
Evaluation procedure
The binding site detections with each algorithm were
made using the individual ChIP samples alone (all except
QuEST and PeakSeq which were not applicable without a
control) as well as with the corresponding negative con-
trols (all except GeneTrack and FindPeaks which do not
provide such an option). Thus, in total, fourteen peak lists
were generated for each ChIP sample. In the following, we
refer to the results involving the control data by adding an
additional C to the name of the method (e.g. the two alter-
native modes of PeakFinder are referred to as PeakFinder
and PeakFinderC). In the STAT6 data, the Thp sample was
used in place of a negative control, although it may con-
tain also some true biological signal. This choice was
motivated by the assumption that the relevant binding
events do not yet occur in the Thp samples [17].
First, we evaluated the reproducibility of the methods
across biological replicates in the NRSF datasets. This
gives indications of the robustness of the methods, as the
biologically relevant binding sites are expected to be
detected in each replicate. The reproducibility between
two peak lists was defined in terms of their overlap, fol-
lowing the approach of [18] to deal with the ambiguity
that a peak in one dataset may overlap multiple peaks in
another dataset. More specifically, the peak regions from
the two peak lists under comparison were first merged
into a union set of n regions. These were then compared
to the original two lists to determine the number of
regions identified in both lists n1. Finally, the reproduci-
bility was defined as n1/n, which obtains the value 1 if all
the peaks are overlapping and the value 0 if none of the
peaks overlaps.
Second, the detected peaks were evaluated in terms of
their overlap with high-scoring sequence motifs. It is
known that transcription factors exhibit binding sequence
specificities, and hence, the genomic coordinate of a peak
should be marked by a canonical binding site motif [8].
Since such motifs are known for the three transcriptionBMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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factors considered in this study (Table 2), they were used
as an external source of information to assess the perform-
ance of the peak detection algorithms. For each sample,
the overlap of the predicted binding sites with the known
motifs was determined using the Genomatix RegionMiner
tool with default settings [19]. To deal with the potential
biases caused by the different peak widths, the motif z-
scores were considered, which measure the overrepresen-
tation of a motif against an equally sized sample of the
genomic background. With GeneTrack and QuEST, which
reported only a single coordinate for each peak, 200 bp
sequences from around the peak calls were utilized, simi-
larly as in [8]. These same regions were also used in the
other overlap calculations.
Finally, the performance of the peak detection algorithms
was evaluated with respect to regions that were confirmed
in independent qPCR experiments to be bound by the
particular transcription factor (true positives) as well as
regions that did not show binding (true negatives) in
these experiments. For NRSF, we used the 83 true positives
and 30 true negatives given in [20]. For FoxA1, 26 true
positives and 12 true negatives were obtained from [21].
For STAT6, we have tested a total of 25 regions at various
levels of read enrichment selected on the basis of manual
inspection to verify the ChIP-seq results at 4 h (Additional
file 1). Of these regions, 17 were confirmed to be bound
by STAT6. The known true positive and true negative
regions in each data allowed us to assess the performance
of the methods in terms of their receiver operating charac-
teristics (ROC), which consider both the sensitivity and
specificity of the detections. Additionally, an empirical
FDR estimate was calculated as the proportion of false
positives among the identified candidate peaks.
An example region identified as a STAT6 binding site at 1 h after polarization with IL4 Figure 1
An example region identified as a STAT6 binding site at 1 h after polarization with IL4. The same region was iden-
tified as a STAT6 binding site with all the fourteen peak detection approaches applied in the present study. The number of 
overlapping reads (y-axis) is shown at each genomic position (x-axis). The horizontal bars below the profile illustrate the 
detected binding regions, as well as the high-scoring STAT6 binding motifs as determined using the Genomatix MatInspector 
tool.
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Results
Characteristics of the detected binding regions
We first investigated the characteristics of the detected
binding sites in terms of an example region in the STAT6
data (Figure 1). Although the same region was detected
with all the algorithms, there were marked differences in
the region boundaries reported by the different software.
In this example, PeakFinder, PeakSeq and Hpeak identi-
fied a relatively long region, whereas FindPeaks, SISSRs,
MACS and CisGenome reported shorter regions. Gene-
Track and QuEST identified only single coordinates with-
out boundary estimates. As GeneTrack was allowed to
detect multiple peaks close to each other, three separate
detection calls were produced. Notably, the ~100 bp
region shared by all of the methods contained also a high-
scoring STAT6 sequence motif, suggesting that the detec-
tion is likely to be a true binding site. This was further sup-
ported by the control Thp sample, which did not show
any enrichment of reads in the region, and the detection
was finally confirmed with qPCR. Interestingly, another
high-scoring binding motif was detected in the lower-
enrichment region that was covered only by the Peak-
Finder, PeakSeq and Hpeak detections but missed with
the other algorithms. The correctness of this detection
remains to be shown in future experiments. In addition to
being an example of a binding site, Figure 1 provides also
a representative illustration of the typical bimodality of
the peak patterns caused by the fact that short reads are
sequenced from both ends of the ChIP DNA fragments.
To get a more general picture of the binding sites identi-
fied by the different algorithms, we calculated the average
peak width for each NRSF, FoxA1 and STAT6 sample listed
in Table 2. In general, PeakFinder and PeakSeq gave the
widest regions (median over the samples > 400 bp),
whereas SISSRs and CisGenome identified the narrowest
peaks (< 100 bp) among the methods that estimate the
boundaries. The average differences between FindPeaks,
MACS and Hpeak were minor (average peak width ~300
bp), but MACS showed largest variability between the
samples. In particular, MACS resulted in narrow peaks (<
100 bp) in our STAT6 data, whereas it produced wider
peaks (~300 bp) in the other datasets. The use of a control
sample did not dramatically affect the average peak
widths with any of the methods.
Number of identifications
The number of detected binding sites varied greatly
depending on the algorithm (Figure 2, upper panel).
PeakFinder and QuEST produced systematically the low-
est numbers of detections, whereas FindPeaks, SISSRs and
MACS tended to identify a larger number of peaks. Gene-
Track, SISSRs, CisGenome and Hpeak showed enormous
variability in the numbers of detections even between the
samples measuring the same transcription factor. For
instance, in the NRSF samples, the number of identifica-
tions ranged from ~3000-5000 to over ~30000. The inves-
tigation of the average overlap between the algorithms
showed that most of the binding sites identified with the
methods producing the shortest lists were also detected
with the other approaches (Figure 2, lower panel). For
instance, nearly all the binding sites identified with Peak-
FinderC were also identified with most of the other algo-
rithms.
Differences in biological conclusions
A closer investigation of the binding site detections in the
STAT6 data revealed the more practical differences
between the algorithms in real applications. Strikingly,
approximately half of the algorithms (PeakFinder, Peak-
FinderC, FindPeaks, CisGenome and PeakSeq) suggested
that there were more binding sites at 1 h than at 4 h,
whereas another half (SISSRs, SISSRsC, MACS, MACSC,
CisGenomeC, Hpeak and HpeakC) identified more bind-
ing sites at 4 h (data not shown). The extreme cases were
CisGenome/PeakSeq and SISSRs/HpeakC, whose results
varied from an ~8-fold decrease to a ~2-fold increase in
the numbers of detections from 1 h to 4 h. This example
demonstrates how the differences in the peak identifica-
tion algorithms may lead to a notably variable overall pic-
ture of the dataset under analysis, emphasizing the
importance of careful assessment of the resulting peak
lists. A plausible technical explanation for the differences
in the numbers of peak detections in different samples
with different read distributions lies in the preferences of
the algorithms. For instance, CisGenome and PeakSeq
rely strongly on the peak heights, whereas SISSRs and
Hpeak consider more the local statistical enrichment pat-
terns. The biological significance of the identified STAT6
binding sites and further analysis of the binding kinetics
remains to be addressed in further studies.
In addition to the number of detected peaks, another
practical question is their physical location in the
genome. Accordingly, we divided the detections into
groups on the basis of their location within 10 kb
upstream/downstream of a transcription start/end site,
within a gene (intragenic), or over 10 kb from a gene
(intergenic) using the CisGenome software [5]. Again,
drastic differences were observed between the algorithms
(Figure 3). For instance, GeneTrack, QuEST and CisGe-
nome suggested that only less than 40% of the STAT6
binding sites at 1 h reside within 10 kb of a gene or are
intragenic, whereas with PeakFinderC, SISSRsC, PeakSeq
and HpeakC the corresponding estimate was over 70%.
Reproducibility of the detections
The two NRSF datasets with biological replicate samples
provided an opportunity to assess the performance of the
algorithms internally by investigating their ability toBMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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Numbers and overlaps of the detected peaks Figure 2
Numbers and overlaps of the detected peaks. The upper panel shows the median number of detected peaks across the 
different ChIP samples and the corresponding minimum and maximum values (error bars). For the clarity of illustration, the 
maximum values with SISSRs (78634) and CisGenome (78551) are cut out from the figure. The lower panel illustrates the 
overlap of the detections with a particular method as compared to all the other methods. The median percentage of overlap-
ping peaks is shown together with the minimum and maximum values (error bars).
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reproduce the detections robustly across the replicates.
When all the peaks were considered, the best reproduci-
bility was observed with PeakFinderC and QuEST (Figure
4). With each method, the use of a negative control sam-
ple improved consistently the reproducibility of the detec-
tions. In general, GeneTrack, SISSRs, CisGenome and
Hpeak gave the lowest reproducibility values, which could
to a large extent be attributed to the fact that huge differ-
ences were observed in the numbers of detections across
the replicates. With these algorithms, the NRSF polyclonal
sample produced markedly more detections than the
other NRSF samples (even over a ten-fold number). Peak-
FinderC and QuEST, on the other hand, identified only a
relatively small number of peaks (2000-3000) and the
number of peaks was consistent across all the three sam-
ples.
When considering only the top 1000 or top 2000 peaks
with each algorithm, all the algorithms showed high
reproducibility and the overall differences between the
methods were typically negligible. Only SISSRsC showed
somewhat lower reproducibility values than the other
algorithms. The lower reproducibility of MACS with top
1000 peaks disappeared when the top 2000 detections
were considered.
External validation using binding motifs
A comparison of the detected peaks with high-scoring
sequence motifs confirmed that all the algorithms identi-
fied binding sites at a highly significant overlap with the
corresponding sequence motif (Figure 5). When the
whole set of detected peaks was investigated with each
algorithm (Figure 5, upper panel), in the NRSF data, the
most significant overlap was observed with QuEST, while
there were no systematic differences between the other
methods. With GeneTrack, SISSRs, CisGenome and
Hpeak, however, the variability between the samples was
large, the NRSF polyclonal sample performing considera-
bly worse than the other two samples. In the FoxA1 data,
MACSC was the best-performing approach in terms of the
sequence motifs, whereas PeakFinderC showed the least
significant motif overlap. In the STAT6 data, the most sig-
nificant overlap was observed with FindPeaks, while
MACS, which was among the best methods in the FoxA1
data, was among the poorest approaches together with
SISSRs and CisGenome.
A representative example demonstrating how biological conclusions may change when different algorithms are applied Figure 3
A representative example demonstrating how biological conclusions may change when different algorithms 
are applied. The physical distribution of the binding sites in the STAT6 data is shown at 1 h after polarization with IL4. The 
binding sites were divided into three categories: 10 kb upstream/downstream of a transcription start/end site, within a gene 
(intragenic), or over 10 kb from a gene (intergenic). The proportion of binding sites in each category is indicated by the col-
ours.
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When focusing only on the top 1000 candidates (Figure 5,
lower panel), the best-performing approaches in the NRSF
and FoxA1 datasets were QuEST and CisGenome, which
produced typically relatively narrow peak regions. This is
in line with the observation that all the methods are likely
to perform reasonably well when detecting the most
prominent peaks (Figure 4), in which case a more specific
detection of the actual binding site can be considered as a
benefit and is captured also by the motif z-score. In prin-
ciple, a narrower peak width can indicate a better resolu-
tion and can be beneficial, for instance, for the discovery
of de novo binding site motifs [5]. The top list size 2000
produced similar results (data not shown). In the STAT6
data, the overall number of peaks was much lower than in
the NRSF and FoxA1 datasets (often even less than 1000
peaks with the default settings), and several algorithms
could detect only less than 2000 peaks even if the detec-
tion thresholds were lowered from their default values. In
the STAT6 data, FindPeaks remained the best-performing
algorithm also when the top 1000 detections were evalu-
ated.
External validation using qPCR
To complement the motif overlap evaluations, qPCR-val-
idated regions were used to assess the sensitivity and spe-
cificity of the methods (Figure 6). In the NRSF data, all the
algorithms performed rather similarly in identifying the
validated positive and negative regions both when consid-
ering the whole set of detections as well as when focusing
on the top peaks only. In the FoxA1 data, the qPCR vali-
dations supported further the good performance of
MACSC when all the detections were used in the evalua-
Reproducibility of the detections across the three NRSF samples Figure 4
Reproducibility of the detections across the three NRSF samples. With each method, the reproducibility was deter-
mined by first creating a union set of the detected regions and then assessing which of these regions were specific to only one 
of the samples under comparison and which were detected in both samples. The median reproducibility is shown together 
with the minimum and maximum values (error bars).
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tion, while only one of the top 1000 binding sites was
included in the set of validated regions. Also in the STAT6
data, the qPCR validations were well in line with the motif
analysis results, suggesting the good performance of Find-
Peaks in these data. Importantly, besides demonstrating
the impact of the dataset on the relative performance of
the algorithms, the qPCR analyses supported the utility of
the motif significance assessments in choosing a suitable
algorithm for peak detection in cases in which the binding
motif is known. In each dataset, the method with the most
significant motif overlap was among the best algorithms
in terms of the qPCR validations.
The qPCR validations enabled also to determine an
empirical FDR for the detections. In the NRSF data, the
empirical FDR was below 0.05 with all the algorithms. In
the FoxA1 data, no negatives were detected with any of the
algorithms, giving an empirical FDR estimate of 0. In the
STAT6 data, the estimated FDR remained typically below
0.2. Notably, however, these values were often markedly
higher than those suggested by the background models of
the algorithms, supporting the earlier observation that
especially the Poisson-based randomization model can
severely underestimate the FDRs [22].
Discussion
The present study evaluated from a practical point of view
the performance of the currently available open source
software for detecting transcription factor binding sites in
ChIP-seq data. A main observation was that the choice of
the algorithm may considerably affect the overall conclu-
sions made from the data (Figure 3). Moreover, there was
no clear winner among the methods that would have out-
performed the other approaches systematically in each
dataset. Instead, the choice of the best method was
strongly dependent on the data under analysis (Figure 5).
External validation of the predicted binding sites using binding motifs Figure 5
External validation of the predicted binding sites using binding motifs. The significance of the overlap of the identified 
peaks with the corresponding high-scoring sequence motifs (see Table 2 for the motif identifiers) was assessed by the Genom-
atix RegionMiner software separately for each transcription factor (columns), either when using all the detected peaks (upper 
panel) or when focusing on the top 1000 peaks only (lower panel). The medians over the ChIP samples (bars) are shown 
together with the minimum and maximum values (error bars).
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While QuEST performed well in the NRSF data, MACS
may be a better choice in the FoxA1 data, whereas Find-
Peaks showed good performance in the STAT6 data.
Below we discuss some practical guidelines for the
researchers, including (i) the choice of an appropriate
algorithm for different study objectives, (ii) the use of a
negative control sample, and (iii) the use of empirical val-
idations.
In most of the currently published ChIP-seq studies, the
choice of the peak detection algorithm lacks detailed
motivation or description (see Table 3 for a set of repre-
sentative cases). Our comparison demonstrates, however,
that this choice warrants careful attention. While most
computational methods perform well under some cir-
cumstances, their behaviour can vary markedly depending
on the dataset under analysis. This is especially true when
the aim is to detect all the potential binding sites of a par-
ticular transcription factor of interest. If only a small set of
best candidate targets are to be detected, then all the meth-
ods performed relatively well in our comparisons (Figure
4). To identify the best candidates, the candidate binding
positions can be prioritized using the peak magnitude
scores or their p-values, provided by the peak detection
software.
When the goal is to identify a comprehensive set of regu-
latory interactions, the major challenge is to determine a
suitable threshold to discriminate true binding sites from
background noise. This was exemplified by the large dif-
ferences in the numbers of peak calls observed with the
different approaches (Figure 2). PeakFinder and Gene-
Track do not provide any statistical estimates of the FDR,
making it difficult to choose an appropriate cutoff.
Although the other algorithms estimate also the statistical
significance of the detections, the accuracy of the estima-
External validation of the predicted binding sites using qPCR Figure 6
External validation of the predicted binding sites using qPCR. The performance of the binding site detection methods 
as assessed by independent qPCR validations, either when using all the detected peaks (upper panel) or when focusing on the 
top 1000 peaks only (lower panel). In total, there were 83, 26 and 17 true positives and 30, 12 and 8 negative validation results 
for NRSF, FoxA1 and STAT6, respectively. The true positive rate (TP, true positives divided by all positives) and the false pos-
itive rate (FP, false positives divided by all negatives) are shown by the bars (median, minimum and maximum in the NRSF data), 
whereas the solid lines illustrate their distance from the optimal performance [(1-TP)2 + FP2]1/2. The dashed lines show the 
empirical estimate of false discovery rate (FDR), calculated as the proportion of false positives among all the identified posi-
tives.
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tion can depend heavily on the choice of the selected null
model [5,23]. While the simplest model assumes that the
background read density is uniform along the genome
and independent between the strands, several authors
have observed that the sequenced control samples show
highly non-uniform behaviour and, in some cases, their
read density patterns are close to those expected from true
binding sites [5,22,23]. This can be due to various rea-
sons, such as sequencing and mapping biases, non-spe-
cific immunoprecipitation or differences in the chromatin
structure [10,24]. Therefore, the use of separate control
samples has been suggested [5,8,10,22], and was also sup-
ported in our comparisons (Figure 4). If experimentally
determined true positive and true negative binding sites
are available, then it is possible to calculate also an empir-
ical FDR for the detections (Figure 6).
Besides the inclusion of a control sample, another impor-
tant decision concerns the type of an appropriate control.
At least three types of controls have been considered: a
non-immunoprecipitated fragmented DNA sample
(input DNA) [12], a ChIP-seq sample using an unspecific
antibody (e.g. IgG) [25], or a ChIP-seq sample under a dif-
ferent cellular condition (e.g. without stimulation) [26].
Further study is needed to determine which control sam-
ple type provides the best outcome in different algo-
rithms. In addition, as the quality of the
immunoprecipitating antibody critically affects the
results, the actual ChIP experiment may also be repeated
with different antibodies [8,24].
If the binding motif of the transcription factor of interest
is known, then it can provide useful information about
the relative performance of the different approaches (Fig-
ure 5). However, there are also transcription factors that
do not require a specific binding motif [27]. Further infor-
mation about the adequacy of the peak detection meth-
ods can be obtained by experimental validations (Figure
6). Since confirmation studies on candidate binding sites
are expensive and time-consuming, however, thorough
experimental validations are relatively rarely done when
reporting large-scale findings. Moreover, it is worth noting
that building an appropriate set of true negatives is a dif-
ficult task, and it has been suggested that the sets of the
previously utilized true negatives may actually contain
also true positives despite their low enrichment ratios in
the qPCR validations [22]. How to choose the best
method directly from the data remains a challenging
future research question.
From the point of view of an ordinary user, a major com-
plication of the peak detection software is the typically
large number of adjustable parameters. While the default
parameters are a natural choice and were applied also by
Table 3: Recent ChIP-seq studies
Transcription
Factor(s)
Organism Algorithm(s) Negative control
sample
qPCR
validations
Reference Time of
publication
Scl/Tal1 Mus musculus FindPeaks no >10 [32] 5/2009
ERalpha Homo sapiens FindPeaks (MACS) yes >10 [33] 5/2009
STAT1 Homo sapiens PeakSeq yes >100 [12] 1/2009
CTCF Homo sapiens SISSRs no not reported [34] 1/2009
Cse4, Ste12 Saccharomyces cerevisiae PeakSeq yes <10 [35] 1/2009
PPARg, RXR Mus musculus FindPeaks no >10 [36] 11/2008
Stat5a, Stat5b Mus musculus MACS yes <10 [25] 11/2008
NRSF, SRF, GABP Homo sapiens QuEST yes not reported [8] 9/2008
FoxA1 Homo sapiens MACS 
(PeakFinder, QuEST, FindPeaks)
yes not reported [10] 9/2008
NRSF Homo sapiens PeakFinder yes >100 [2] 6/2007
Representative examples of recent ChIP-seq studies with publicly available datasets were collected from the Gene Expression Omnibus (GEO). 
Additionally, the public datasets used in the present study were included. The column Algorithm(s) indicates the algorithm applied in the original 
study. If other algorithms were also considered, they are listed in the brackets. The column qPCR validations indicates the level of experimental 
validation in terms of the numbers of validated regions.BMC Genomics 2009, 10:618 http://www.biomedcentral.com/1471-2164/10/618
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us, they may not be optimal for the particular data under
analysis. On the other hand, if an algorithm lacks the pos-
sibility to easily adjust the parameters properly, it can be
regarded as a weakness of the method. Other critical issues
in ChIP-seq data analysis are the memory requirements
for the computer and the diversity of the current data for-
mats. The required input formats of the peak detection
software as well as their output peak lists are far from
being standardized, neither are the output formats pro-
duced by the different read alignment software. Further
technical challenges include, for instance, the quality of
the aligned reads and the required depth of sequencing
[22]. Also the interpretation of the results poses its own
challenges. Even if a comprehensive and unbiased set of
binding sites could be determined with ChIP-seq, the
identified sites may not all be functional regulatory ele-
ments that have an impact on transcription. Instead, it is
possible that several non-functional detections are made
as a consequence of biological noise [28,29].
Despite the challenges, the next-generation DNA sequenc-
ing has a great potential to accelerate biological and bio-
medical research by enabling a comprehensive analysis of
genomes, transcriptomes and interactomes to be per-
formed routinely without having the resources of large
genomic centres [3]. While several issues remain to be
solved regarding, for instance, the optimization of the
peak detection algorithms, already the current results sup-
port the utility of the ChIP-seq technique. In our compar-
isons, for example, all the algorithms identified binding
sites with highly significant overlap with the correspond-
ing known sequence motif (Figure 5), and the most prom-
inent peaks were typically detected robustly across
independent experiments (Figure 4). In addition to tran-
scription factor binding, a wide range of other biological
phenomena can be investigated, such as chromosome
conformation, genetic variation, and RNA expression
(RNA-seq) to detect, for instance, differential splicing,
microRNA and other non-coding RNAs [3,30,31].
With the growing importance of the technology, rigorous
computational approaches to transform the large datasets
into biological knowledge are required to truly leverage
the potential of these data. Rather than introducing a
number of closely related algorithms, it is critical to objec-
tively evaluate their performance to provide practical
guidance to the researchers analysing their data and to the
developers of the algorithms to evaluate their new ideas.
An important future direction is also to effectively inte-
grate ChIP-seq data with other types of datasets, such as
those generated in siRNA interference experiments, to
improve the detection of target genes.
Conclusions
ChIP-seq combines chromatin immunoprecipitation with
next-generation sequencing to identify in vivo protein-
DNA interactions on a genome-wide scale. With the
increasing popularity of the ChIP-seq technology, a
number of algorithms have been presented to analyse the
resulting datasets. However, only little is known about
their relative merits and limitations in practical applica-
tions. Rather than introducing a range of closely related
procedures, it is therefore crucial to objectively assess their
performance in practice. In the present study, we compare
systematically the current state-of-the-art of detecting
transcription factor binding sites from ChIP-seq data
under a variety of practical research settings, including
reproducibility across biological replicates as well as com-
parisons to high-scoring binding motifs or independent
experimental validations. Our results suggest that the
optimal choice of the algorithm depends heavily on the
dataset under analysis. In addition to providing practical
guidance to the users of the ChIP-seq technology, our sys-
tematic evaluation framework is also a useful reference to
the developers of improved algorithms.
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